NYKD: Nykode Therapeutics to Present at Jefferies Healthcare Conference
Oslo, Norway, May 30, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that its Chief Executive
Officer, Michael Engsig, will present and host 1x1 meetings at the 2023
Jefferies Healthcare Conference in New York on Wednesday, June 7, 2023, at 10:00
a.m. ET / 4:00 p.m. CET.
The live and archived webcast of the presentation can be accessed in the
Investors section of the Company's website at https://nykode.com/investors.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses which
correlates with clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer